{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:12:39Z","timestamp":1771006359832,"version":"3.50.1"},"reference-count":76,"publisher":"Begell House","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Environ Pathol Toxicol Oncol"],"published-print":{"date-parts":[[2026]]},"abstract":"<p>Colorectal cancer (CRC) is a serious malignancy. Retinoic acid (RA) can inhibit cancer cell growth, promote cancer cell apoptosis, and hold significant importance for tumor prognosis. We utilized TCGA public data to screen RA-related genes linked with survival. Based on RA-related genes, the CRC prognostic model was generated by Cox regression analysis. Subsequently, immune infiltration analysis, functional enrichment analysis of differentially expressed genes (DEGs), tumor mutation analysis, and drug prediction were carried out based on the high-risk (HR) and low-risk (LR) groups identified in the prognostic model. We identified 10 RA-related genes associated with CRC. A prognostic model was constructed based on RA-related genes. CRC patients were divided into HR and LR groups. Immune infiltration analysis demonstrated that cells such as B cells, iDCs, and mast cells had higher infiltration levels in the LR group (&lt;i&gt;P&lt;\/i&gt; &amp;#60; 0.05). The results of DEG enrichment analysis of HR and LR groups uncovered that DEGs were mainly enriched in Alcoholism, regionalization, nucleosome, DNA packaging complex, and other biological processes. Drug sensitivity prediction results revealed that AZ628, CGP-082996, CKM, Dasatinib, GNF-2, Saracatinib, Sorafenib, WH-4-023, and WZ-1-84 were more sensitive for patients in the HR group. AKT inhibitor VIII, Gemcitabine, JW-7-52-1, Mitomycin, NSC-87877, PAC-1, Pyrimethamine, QS11, and Roscovitine were more sensitive for those in the LR group. Our project identified correlations between RA-related genes and CRC. The model genes identified are essential indicators for evaluating CRC prognosis and further treating CRC.<\/p>","DOI":"10.1615\/jenvironpatholtoxicoloncol.2025055211","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T13:22:53Z","timestamp":1743168173000},"page":"25-41","source":"Crossref","is-referenced-by-count":0,"title":["Prediction of Prognosis, Tumor Microenvironment, and Drug Treatment of Colorectal Cancer Based on Retinoic Acid-Related Genes"],"prefix":"10.1615","volume":"45","author":[{"given":"Yuecheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"613","reference":[{"key":"2","doi-asserted-by":"crossref","unstructured":"Sawicki T, Ruszkowska M, Danielewicz A, Nied\u00c5\u00bawiedzka E, Ar\u00c5\u0082ukowicz T, Przyby\u00c5\u0082owicz KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers. 2021;13(9):2025.","DOI":"10.3390\/cancers13092025"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Wu CW, Lui RN. Early-onset colorectal cancer: Current insights and future directions. World J Gastrointest Oncol. 2022;14(1):230-41.","DOI":"10.4251\/wjgo.v14.i1.230"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Fritz CDL, Otegbeye EE, Zong X, Demb J, Nickel KB, Olsen MA, Mutch M, Davidson NO, Gupta S, Cao Y. Red-flag signs and symptoms for earlier diagnosis of early-onset colorectal cancer. J Natl Cancer Inst. 2023;115(8):909-16.","DOI":"10.1093\/jnci\/djad068"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Plumb AA, Pathiraja F, Nickerson C, Wooldrage K, Burling D, Taylor SA, Atkin WS, Halligan S. Appearances of screen-detected versus symptomatic colorectal cancers at CT colonography. Eur Radiol. 2016;26(12):4313-22.","DOI":"10.1007\/s00330-016-4293-7"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer Lett. 2014;345(2):235-41.","DOI":"10.1016\/j.canlet.2013.07.032"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Kawasaki K, Torisu T, Nagahata T, Esaki M, Kurahara K, Eizuka M, Tanaka Y, Fujiwara M, Kawatoko S, Oshiro Y, Yamada S, Ikegami K, Fujioka S, Fuyuno Y, Matsuno Y, Umeno J, Moriyama T, Kitazono T, Sugai T, Matsumoto T. Role of barium enema examination for the diagnosis of submucosal invasion depth in T1 colorectal cancers. Cancer Imaging. 2021;21(1):66.","DOI":"10.1186\/s40644-021-00437-z"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Keraliya A, Yu HS, Uyeda JW. CT imaging findings of complications of optical colonoscopy. Emerg Radiol. 2022;29(5):915-23.","DOI":"10.1007\/s10140-022-02058-w"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Morris VK, Kennedy EB, Baxter NN, Benson AB, 3rd, Cercek A, Cho M, Ciombor KK, Cremolini C, Davis A, Deming DA, Fakih MG, Gholami S, Hong TS, Jaiyesimi I, Klute K, Lieu C, Sanoff H, Strickler JH, White S, Willis JA, Eng C. Treatment of metastatic colorectal cancer: ASCO Guideline. J Clin Oncol. 2023;41(3):678-700.","DOI":"10.1200\/JCO.22.01690"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Guo L, Wang Y, Yang W, Wang C, Guo T, Yang J, Shao Z, Cai G, Cai S, Zhang L, Hu X, Xu Y. Molecular profiling provides clinical insights into targeted and immunotherapies as well as colorectal cancer prognosis. Gastroenterology. 2023;165(2):414-28.e7.","DOI":"10.1053\/j.gastro.2023.04.029"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Li C, Sun YD, Yu GY, Cui JR, Lou Z, Zhang H, Huang Y, Bai CG, Deng LL, Liu P, Zheng K, Wang YH, Wang QQ, Li QR, Wu QQ, Liu Q, Shyr Y, Li YX, Chen LN, Wu JR, Zhang W, Zeng R. Integrated omics of metastatic colorectal cancer. Cancer Cell. 2020;38(5):734-47.e9.","DOI":"10.1016\/j.ccell.2020.08.002"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Wan YJ. Retinoic acid and its receptors. Am J Surg. 1993;166(1):50-3.","DOI":"10.1016\/S0002-9610(05)80581-1"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Dawson MI, Zhang XK. Discovery and design of retinoic acid receptor and retinoid X receptor class- and subtype-selective synthetic analogs of all-trans-retinoic acid and 9-cis-retinoic acid. Curr Med Chem. 2002;9(6): 623-37.","DOI":"10.2174\/0929867023370789"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Liang C, Qiao G, Liu Y, Tian L, Hui N, Li J, Ma Y, Li H, Zhao Q, Cao W, Liu H, Ren X. Overview of all-trans-retinoic acid (ATRA) and its analogues: Structures, activities, and mechanisms in acute promyelocytic leukaemia. Eur J Med Chem. 2021;220:113451.","DOI":"10.1016\/j.ejmech.2021.113451"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Blazsek I, Farabos C, Musset M, Goldschmidt E, Comisso M, Benavides M, Wang ZY, Labat ML, Math\u00e9 G, Misset JL. Retinoic acid in mono- or combined differentiation therapy of myelodysplasia and acute promyelocytic leukemia. Biomed Pharmacother. 1991;45(4-5): 169-77.","DOI":"10.1016\/0753-3322(91)90104-2"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Szymanski L, Skopek R, Palusinska M, Schenk T, Stengel S, Lewicki S, Kraj L, Kaminski P, Zelent A. Retinoic acid and its derivatives in skin. Cells. 2020;9(12):2660.","DOI":"10.3390\/cells9122660"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Devalaraja S, To TKJ, Folkert IW, Natesan R, Alam MZ, Li M, Tada Y, Budagyan K, Dang MT, Zhai L, Lobel GP, Ciotti GE, Eisinger-Mathason TSK, Asangani IA, Weber K, Simon MC, Haldar M. Tumor-derived retinoic acid regulates intratumoral monocyte differentiation to promote immune suppression. Cell. 2020;180(6):1098-114.e16.","DOI":"10.1016\/j.cell.2020.02.042"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Tilsed CM, Morales MLO, Zemek RM, Gordon BA, Piggott MJ, Nowak AK, Fisher SA, Lake RA, Lesterhuis WJ. Tretinoin improves the anti-cancer response to cyclophosphamide, in a model-selective manner. BMC Cancer. 2024;24(1):203.","DOI":"10.1186\/s12885-024-11915-5"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Lee MO, Han SY, Jiang S, Park JH, Kim SJ. Differential effects of retinoic acid on growth and apoptosis in human colon cancer cell lines associated with the induction of retinoic acid receptor beta. Biochem Pharmacol. 2000;59(5):485-96.","DOI":"10.1016\/S0006-2952(99)00355-X"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Li J, Xiang Q, Wang M, Zhang H, Liang R. All-trans retinoic acid enhances chemosensitivity to 5-FU by targeting miR-378c\/E2F7 axis in colorectal cancer. J Oncol. 2021;2021:5338934.","DOI":"10.1155\/2021\/5338934"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Zhang X, Wen Z, Wang Q, Ren L, Zhao S. A novel stratification framework based on anoikis-related genes for predicting the prognosis in patients with osteosarcoma. Front Immunol. 2023;14:1199869.","DOI":"10.3389\/fimmu.2023.1199869"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Dai S, Liu T, Liu XQ, Li XY, Xu K, Ren T, Luo F. Identification of an immune-related signature predicting survival risk and immune microenvironment in gastric cancer. Front Cell Dev Biol. 2021;9:687473.","DOI":"10.3389\/fcell.2021.687473"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Liu X, Rong Y, Huang D, Liang Z, Yi X, Wu F, Zhu D, Mo S, Nong W, Li H. Altered genes and biological functions in response to severe burns. Biomed Res Int. 2021;2021:8836243.","DOI":"10.1155\/2021\/8836243"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Wei J, Wang J, Chen X, Zhang L, Peng M. Novel application of the ferroptosis-related genes risk model associated with disulfidptosis in hepatocellular carcinoma prognosis and immune infiltration. PeerJ. 2024;12:e16819.","DOI":"10.7717\/peerj.16819"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Hou Y, Zhang R, Zong J, Wang W, Zhou M, Yan Z, Li T, Gan W, Lv S, Zeng Z, Yang M. Comprehensive analysis of a cancer-immunity cycle-based signature for predicting prognosis and immunotherapy response in patients with colorectal cancer. Front Immunol. 2022;13:892512.","DOI":"10.3389\/fimmu.2022.892512"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Ji C, Shrestha S, Jumuddin FA. To establish a nomogram prediction of prostate cancer based on pyroptosis-related genes that affect the immune microenvironment. Asian Pac J Cancer Prev. 2024;25(7):2319-27.","DOI":"10.31557\/APJCP.2024.25.7.2319"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: Efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747-56.","DOI":"10.1101\/gr.239244.118"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Yan C, Niu Y, Li F, Zhao W, Ma L. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma. J Transl Med. 2022;20(1):455.","DOI":"10.1186\/s12967-022-03632-z"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Wan ML, Wang Y, Zeng Z, Deng B, Zhu BS, Cao T, Li YK, Xiao J, Han Q, Wu Q. Colorectal cancer (CRC) as a multifactorial disease and its causal correlations with multiple signaling pathways. Biosci Rep. 2020;40(3):BSR20200265.","DOI":"10.1042\/BSR20200265"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145-64.","DOI":"10.3322\/caac.21601"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Modarai SR, Gupta A, Opdenaker LM, Kowash R, Masters G, Viswanathan V, Zhang T, Fields JZ, Boman BM. The anti-cancer effect of retinoic acid signaling in CRC occurs via decreased growth of ALDH+ colon cancer stem cells and increased differentiation of stem cells. Oncotarget. 2018;9(78):34658-69.","DOI":"10.18632\/oncotarget.26157"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Liu K, Zheng M, Lu R, Du J, Zhao Q, Li Z, Li Y, Zhang S. The role of CDC25C in cell cycle regulation and clinical cancer therapy: A systematic review. Cancer Cell Int. 2020;20:213.","DOI":"10.1186\/s12935-020-01304-w"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Maimaiti A, Aizezi A, Anniwaer J, Ayitula, Ali B, Dilixiati M. Zinc finger of the cerebellum 5 promotes colorectal cancer cell proliferation and cell cycle progression through enhanced CDK1\/CDC25c signaling. Arch Med Sci. 2021;17(2):449-61.","DOI":"10.5114\/aoms.2019.89677"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Yousef GM, Magklara A, Diamandis EP. KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics. 2000;69(3):331-41.","DOI":"10.1006\/geno.2000.6346"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Li Q, Zhou X, Fang Z, Zhou H. Knockdown of KLK12 inhibits viability and induces apoptosis in human colorectal cancer HT-29 cell line. Int J Mol Med. 2019;44(5):1667-76.","DOI":"10.3892\/ijmm.2019.4327"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Belviso S, Iuliano R, Amato R, Perrotti N, Menniti M. The human asparaginase enzyme (ASPG) inhibits growth in leukemic cells. PLoS One. 2017;12(5):e0178174.","DOI":"10.1371\/journal.pone.0178174"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Peng X, Zheng T, Guo Y, Zhu Y. Amino acid metabolism genes associated with immunotherapy responses and clinical prognosis of colorectal cancer. Front Mol Biosci. 2022;9:955705.","DOI":"10.3389\/fmolb.2022.955705"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Wang Z, Huang C, Wu J, Zhang H, Shao Y, Fu Z. Analysis of the prognostic significance and immune infiltration of the amino acid metabolism-related genes in colon adenocarcinoma. Front Genet. 2022;13:951461.","DOI":"10.3389\/fgene.2022.951461"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Ren Y, He S, Feng S, Yang W. A prognostic model for colon adenocarcinoma patients based on ten amino acid metabolism related genes. Front Public Health. 2022;10: 916364.","DOI":"10.3389\/fpubh.2022.916364"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Moody DB, Suliman S. CD1: From molecules to diseases. F1000Research. 2017;6:1909.","DOI":"10.12688\/f1000research.12178.1"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Van Rhijn I. Do antigen-presenting CD1a, CD1b, CD1c, and CD1d molecules bind different self-lipids? Trends Immunol. 2023;44(10):757-9.","DOI":"10.1016\/j.it.2023.08.010"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Halestrap AP. The SLC16 gene family-Structure, role and regulation in health and disease. Mol Aspects Med. 2013;34(2-3):337-49.","DOI":"10.1016\/j.mam.2012.05.003"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Deng H, Chen S, Yuan X, Zhang J. Transcriptome sequencing analysis of the effect of \u00ce\u00b2-elemene on colorectal cancer from the lncRNA-miRNA-mRNA perspective. Genet Res. 2022;2022:5896296.","DOI":"10.1155\/2022\/5896296"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Fu Z, Liang X, Shi L, Tang L, Chen D, Liu A, Shao C. SYT8 promotes pancreatic cancer progression via the TNNI2\/ERR\u00ce\u00b1\/SIRT1 signaling pathway. Cell Death Discov. 2021;7(1):390.","DOI":"10.1038\/s41420-021-00779-4"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Kanda M, Murotani K, Tanaka H, Miwa T, Umeda S, Tanaka C, Kobayashi D, Hayashi M, Hattori N, Suenaga M, Yamada S, Nakayama G, Fujiwara M, Kodera Y. A novel dual-marker expression panel for easy and accurate risk stratification of patients with gastric cancer. Cancer Med. 2018;7(6):2463-71.","DOI":"10.1002\/cam4.1522"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Du M, Wang Y, Vallis J, Shariati M, Parfrey PS, McLaughlin JR, Wang PP, Zhu Y. Associations between polymorphisms in leptin and leptin receptor genes and colorectal cancer survival. Cancer Biol Med. 2023;20(6):438-51.","DOI":"10.20892\/j.issn.2095-3941.2022.0635"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Al-Shibli SM, Harun N, Ashour AE, Mohd Kasmuri MHB, Mizan S. Expression of leptin and leptin receptors in colorectal cancer-an immunohistochemical study. PeerJ. 2019;7:e7624.","DOI":"10.7717\/peerj.7624"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Wang HJ, Wang L, Song SS, He XL, Pan HY, Hu ZM, Mou XZ. Decreased expression of PTH1R is a poor prognosis in hepatocellular carcinoma. Cancer Biomark. 2018;21(3):723-30.","DOI":"10.3233\/CBM-170823"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Liu J, Li H, Sun L, Shen S, Zhou Q, Yuan Y, Xing C. Epigenetic alternations of microRNAs and DNA methylation contribute to liver metastasis of colorectal cancer. Dig Dis Sci. 2019;64(6):1523-34.","DOI":"10.1007\/s10620-018-5424-6"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, Longacre M. Cancer development, progression, and therapy: An epigenetic overview. Int J Mol Sci. 2013;14(10):21087-113.","DOI":"10.3390\/ijms141021087"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Novikov NM, Zolotaryova SY, Gautreau AM, Denisov EV. Mutational drivers of cancer cell migration and invasion. Br J Cancer. 2021;124(1):102-14.","DOI":"10.1038\/s41416-020-01149-0"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Liu Z, Wang L, Guo C, Liu L, Jiao D, Sun Z, Wu K, Zhao Y, Han X. TTN\/OBSCN 'Double-Hit' predicts favourable prognosis, 'immune-hot' subtype and potentially better immunotherapeutic efficacy in colorectal cancer. J Cell Mol Med. 2021;25(7):3239-51.","DOI":"10.1111\/jcmm.16393"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Zhang L, Shay JW. Multiple roles of APC and its therapeutic implications in colorectal cancer. J Natl Cancer Inst. 2017;109(8):djw332.","DOI":"10.1093\/jnci\/djw332"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Sa R, Song H, Wei M, Su H, Hong Y, Zhou L, Bai Y. The impact of APC polymorphisms on the transition from polyps to colorectal cancer (CRC). Gene. 2020;740:144486.","DOI":"10.1016\/j.gene.2020.144486"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Liu Z, Gu Y, Li X, Zhou L, Cheng X, Jiang H, Huang Y, Zhang Y, Xu T, Yang W, Huang Q. Mucin 16 promotes colorectal cancer development and progression through activation of janus kinase 2. Dig Dis Sci. 2022;67(6):2195-208.","DOI":"10.1007\/s10620-021-07004-3"},{"key":"56","doi-asserted-by":"crossref","unstructured":"Hossain SM, Shetty J, Tha KK, Chowdhury EH. \u00ce\u00b1-ketoglutaric acid-modified carbonate apatite enhances cellular uptake and cytotoxicity of a raf-kinase inhibitor in breast cancer cells through inhibition of MAPK and PI-3 kinase pathways. Biomedicines. 2019;7(1):4.","DOI":"10.3390\/biomedicines7010004"},{"key":"57","doi-asserted-by":"crossref","unstructured":"Huang H, Li Q, Tu X, Yu D, Zhou Y, Ma L, Wei K, Gao Y, Zhao G, Han R, Ye F, Ke C. DNA hypomethylation patterns and their impact on the tumor microenvironment in colorectal cancer. Cell Oncol. 2024;47(4):1375-89.","DOI":"10.1007\/s13402-024-00933-x"},{"key":"58","doi-asserted-by":"crossref","unstructured":"Lindauer M, Hochhaus A. Dasatinib. Recent Results Cancer Res. 2010;184:83-102.","DOI":"10.1007\/978-3-642-01222-8_7"},{"key":"59","doi-asserted-by":"crossref","unstructured":"Scott AJ, Song EK, Bagby S, Purkey A, McCarter M, Gajdos C, Quackenbush KS, Cross B, Pitts TM, Tan AC, Eckhardt SG, Fenton H, Arcaroli J, Messersmith WA. Evaluation of the efficacy of dasatinib, a Src\/Abl inhibitor, in colorectal cancer cell lines and explant mouse model. PLoS One. 2017;12(11):e0187173.","DOI":"10.1371\/journal.pone.0187173"},{"key":"60","doi-asserted-by":"crossref","unstructured":"Nakachi I, Helfrich BA, Spillman MA, Mickler EA, Olson CJ, Rice JL, Coldren CD, Heasley LE, Geraci MW, Stearman RS. PTTG1 levels are predictive of saracatinib sensitivity in ovarian cancer cell lines. Clin Transl Sci. 2016;9(6):293-301.","DOI":"10.1111\/cts.12413"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Arcaroli JJ, Touban BM, Tan AC, Varella-Garcia M, Powell RW, Eckhardt SG, Elvin P, Gao D, Messersmith WA. Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. Clin Cancer Res. 2010;16(16):4165-77.","DOI":"10.1158\/1078-0432.CCR-10-0066"},{"key":"62","doi-asserted-by":"crossref","unstructured":"Keating GM. Sorafenib: A review in hepatocellular carcinoma. Target Oncol. 2017;12(2):243-53.","DOI":"10.1007\/s11523-017-0484-7"},{"key":"63","doi-asserted-by":"crossref","unstructured":"Porta C, Paglino C, Imarisio I, Ferraris E. Sorafenib tosylate in advanced kidney cancer: Past, present and future. Anticancer Drugs. 2009;20(6):409-15.","DOI":"10.1097\/CAD.0b013e32831fb500"},{"key":"64","doi-asserted-by":"crossref","unstructured":"Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Pena C, Moln\u00e1r I, Schlumberger MJ. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319-28.","DOI":"10.1016\/S0140-6736(14)60421-9"},{"key":"65","doi-asserted-by":"crossref","unstructured":"Hu JM, Chang YL, Hsieh CC, Huang SM. The synergistic cytotoxic effects of GW5074 and sorafenib by impacting mitochondrial functions in human colorectal cancer cell lines. Front Oncol. 2022;12:925653.","DOI":"10.3389\/fonc.2022.925653"},{"key":"66","doi-asserted-by":"crossref","unstructured":"Revathidevi S, Munirajan AK. Akt in cancer: Mediator and more. Semin Cancer Biol. 2019;59:80-91.","DOI":"10.1016\/j.semcancer.2019.06.002"},{"key":"67","doi-asserted-by":"crossref","unstructured":"Yu C, Sun P, Zhou Y, Shen B, Zhou M, Wu L, Kong M. Inhibition of AKT enhances the anti-cancer effects of Artemisinin in clear cell renal cell carcinoma. Biomed Pharmacother. 2019;118:109383.","DOI":"10.1016\/j.biopha.2019.109383"},{"key":"68","doi-asserted-by":"crossref","unstructured":"Huang Y, Yin D, Wu L. Identification of cuproptosis-related subtypes and development of a prognostic signature in colorectal cancer. Sci Rep. 2022;12(1):17348.","DOI":"10.1038\/s41598-022-22300-2"},{"key":"69","doi-asserted-by":"crossref","unstructured":"Noble S, Goa KL. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 1997;54(3):447-72.","DOI":"10.2165\/00003495-199754030-00009"},{"key":"70","doi-asserted-by":"crossref","unstructured":"Zeng X, Sun L, Ling X, Jiang Y, Shen J, Liang L, Zhang X. Comprehensive analysis identifies novel targets of gemcitabine to improve chemotherapy treatment strategies for colorectal cancer. Front Endocrinol. 2023;14:1170526.","DOI":"10.3389\/fendo.2023.1170526"},{"key":"71","doi-asserted-by":"crossref","unstructured":"Verweij J, Pinedo HM. Mitomycin C: Mechanism of action, usefulness and limitations. Anticancer Drugs. 1990;1(1):5-13.","DOI":"10.1097\/00001813-199010000-00002"},{"key":"72","doi-asserted-by":"crossref","unstructured":"Hortobagyi GN. Mitomycin-C in breast cancer. Semin Oncol. 1985;12(4 Suppl 6):65-70.","DOI":"10.1016\/0305-7372(85)90007-6"},{"key":"73","doi-asserted-by":"crossref","unstructured":"Schnall S, Macdonald JS. Mitomycin therapy in gastric cancer. Oncology. 1993;50(Suppl 1):70-7.","DOI":"10.1159\/000227249"},{"key":"74","doi-asserted-by":"crossref","unstructured":"Xie BY, Wu AW. Organoid culture of isolated cells from patient-derived tissues with colorectal cancer. Chin Med J. 2016;129(20):2469-75.","DOI":"10.4103\/0366-6999.191782"},{"key":"75","doi-asserted-by":"crossref","unstructured":"Xie L, Cheng L, Wei Y. Mitomycin C enhanced the antitumor efficacy of Rocaglamide in colorectal cancer. Pathol Res Pract. 2023;243:154350.","DOI":"10.1016\/j.prp.2023.154350"},{"key":"76","unstructured":"Mandelbrot L, Kieffer F, Sitta R, Laurichesse-Delmas H, Winer N, Mesnard L, Berrebi A, Le Bouar G, Bory JP, Cordier AG, Ville Y, Perrotin F, Jouannic JM, Biquard F, d'Ercole C, Houfflin-Debarge V, Villena I, Thi\u00e9baut R. Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: A multicenter, randomized trial. Am J Obstet Gynecol. 2018;219(4):386.e1-9."},{"key":"77","doi-asserted-by":"crossref","unstructured":"Dong H, Hu L, Li W, Shi M, He L, Wang C, Hu Y, Wang H, Wen C, Liu H, Yang X. Pyrimethamine inhibits cell growth by inducing cell senescence and boosting CD8(+) T-cell mediated cytotoxicity in colorectal cancer. Mol Biol Rep. 2022;49(6):4281-92.","DOI":"10.1007\/s11033-022-07262-y"}],"container-title":["Journal of Environmental Pathology, Toxicology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/0fbf9600547824a6\/JEP(T)-55211.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:42:31Z","timestamp":1771004551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/0ff459a57a4c08d0,2fb6b68a749338cd,0fbf9600547824a6.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1615\/jenvironpatholtoxicoloncol.2025055211","relation":{},"ISSN":["0731-8898"],"issn-type":[{"value":"0731-8898","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}